Insight into the Interactions between Novel Coumarin Derivatives and Human A(3) Adenosine Receptors

• Type: Article in International Scientific Journal
• Date: 2014

Authors

Maria J Joao Matos (Author) Other; Santiago Vilar (Author) Other; Sonja Kachler (Author) Other; Andre Fonseca (Author) Other; Lourdes Santana (Author) Other; Eugenio Uriarte (Author) Other; Fernanda Borges (Author) FCUP; Nicholas P Tatonetti (Author) Other; Karl Norbert Klotz (Author) Other

Journal

Title: ChemMedChem

Vol. 9

ISSN: 1860-7179

Publisher: Wiley-Blackwell

Indexing

ISI Web of Knowledge - 14 Citations

Scopus - 14 Citations

Scientific classification

FOS: Medical and Health sciences > Basic medicine

Other information

Authenticus ID: P-009-VRM

Abstract (EN): A study focused on the discovery of new chemical entities based on the 3-arylcoumarin scaffold was performed with the aim of finding new adenosine receptor (AR) ligands. Thirteen synthesized compounds were evaluated by radioligand binding (A(1), A(2A), and A(3)) and adenylyl cyclase activity (A(2B)) assays in order to study their affinity for the four human AR (hAR) subtypes. Seven of the studied compounds proved to be selective A(3)AR ligands, with 3-(4'-methylphenyl)-8-(2-oxopropoxy) coumarin (12) being the most potent (K-i=634 nm). None of the compounds showed affinity for the A2B receptor, while four compounds were found to be nonselective AR ligands for the other three subtypes. Docking simulations were carried out to identify the hypothetical binding mode and to rationalize the interaction of these types of coumarin derivatives with the binding site of the three ARs to which binding was observed. The results allowed us to conclude that the 3-arylcoumarin scaffold composes a novel and promising class of A(3)AR ligands. ADME properties were also calculated, with the results suggesting that these compounds are promising leads for the identification of new drug candidates.

Language: English

Type (Professor's evaluation): Scientific